BioDelivery Sciences Appoints Jeff Bailey Interim CEO
11 Mayo 2020 - 7:30AM
BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly
growing specialty pharmaceutical company dedicated to patients
living with serious and complex chronic conditions, today announced
that Jeffrey A. Bailey, a member of the Company’s Board of
Directors, has been named Interim Chief Executive Officer (CEO),
effective today. Mr. Bailey succeeds Herm Cukier as CEO.
“On behalf of the Board and our entire Company, I am excited
that Jeff Bailey has agreed to serve as Interim CEO," stated Peter
Greenleaf, Chairman of the Board of Directors of BDSI. "The Board
thanks Herm Cukier for his leadership during a transformative time
in the Company's history, and we wish him the best in the
future.”
“Jeff Bailey has a terrific track record of leading
organizations and delivering shareholder value,” stated Kevin
Kotler, Chair of the Nominating & Corporate Governance
Committee and founder of Broadfin Capital. “We look forward
to his help in refining and driving our long-term strategic
plan.”
Mr. Bailey has an accomplished record in leading
both public and private healthcare companies where he has leveraged
his diverse leadership experiences in various functional areas
including commercial, supply chain and business development, as
well as in-licensing and transactions. His experiences
include a 20+ year career at Johnson & Johnson/Janssen
Pharmaceutica as well as a tenure as Operating Unit President at
Novartis Pharmaceuticals, Chief Commercial Officer at King
Pharmaceuticals, Chief Operating Officer at Fougera
Pharmaceuticals, and Chairman and CEO of Neurovance. Mr.
Bailey also served as President and CEO of Lantheus Medical
Imaging, Inc, taking the company public in 2015. Most
recently, he was the CEO of IlluminOss Medical, Inc, which was
acquired last month.
“I look forward to working with the BDSI team in
taking the Company to the next level,” stated Jeff Bailey.
“BDSI has therapeutically differentiated products that really make
a difference in patients’ lives. We have so much opportunity
in front of us.”
Mr. Bailey has served as Chairman of Aileron Therapeutics
since March 2018 and as a Board Member of Madison Vaccines, a
privately held biopharmaceutical company, since October
2017. Mr. Bailey received a Bachelor of Science
Degree from Rutgers University.
ABOUT BIODELIVERY SCIENCES INTERNATIONAL,
INC.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a
commercial-stage specialty pharmaceutical company dedicated to
patients living with chronic conditions. BDSI has built a portfolio
of products that includes utilizing its novel and proprietary
BioErodible MucoAdhesive (BEMA®) technology to develop and
commercialize, either on its own or in partnership with third
parties, new applications of proven therapies aimed at addressing
important unmet medical needs. BDSI's marketed products address
serious and debilitating conditions, including chronic pain, opioid
dependence, and opioid-induced constipation.
© 2020 BioDelivery Sciences International,
Inc. All rights reserved.
Contact:
Terry Coelho, Chief Financial Officer(919) 551-5281e-mail:
BDSI_IR@bdsi.com
BioDelivery Sciences (NASDAQ:BDSI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BioDelivery Sciences (NASDAQ:BDSI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024